In Another Blow For HDL Therapies, Cerenis’ CER-001 Stumbles In Phase II
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Intravenous HDL mimetic candidate CER-001 misses endpoint for regression of plaque in Phase IIb study, but Cerenis indicates it’s still committed to the therapy.
You may also be interested in...
Time, And Price, Are Right To Prescribe Statins To the Masses
With cheap, proven statins aplenty, cost constraints are “off the table” when it comes to vastly broadening primary prevention, authors of new cholesterol guidelines say at the 2013 AHA meeting. However, evidence for drugs to lower triglycerides and boost HDL is lacking, and focus should be on lifestyle change, they say.
Resverlogix’s Reprieve: ASSURE Results Suggest RVX-208 Works When Given With Crestor
While the ASSURE study failed overall, it turns out that a subset taking the HDL-raising drug candidate with the statin Crestor did benefit from treatment; Resverlogix is now planning to develop the combination.
HPS2-THRIVE Post-Mortem: Lessons Learned For CV Drug Developers
While risks clearly outweigh benefits for niacin as an add-on therapy in the more than 25,000-patient HPS2-THRIVE study, investigators argue that the door is still open for other HDL-raising drugs. One panelist at the ACC meeting where results were presented calls for smaller, more targeted trials in the future.